Candriam Luxembourg S.C.A. Reduces Stock Position in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE)

Share on StockTwits

Candriam Luxembourg S.C.A. lowered its stake in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) by 13.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 121,500 shares of the biopharmaceutical company’s stock after selling 19,000 shares during the quarter. Candriam Luxembourg S.C.A.’s holdings in Ultragenyx Pharmaceutical were worth $5,189,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Morgan Stanley increased its position in Ultragenyx Pharmaceutical by 272.1% in the 2nd quarter. Morgan Stanley now owns 84,168 shares of the biopharmaceutical company’s stock valued at $5,345,000 after buying an additional 61,549 shares in the last quarter. State of New Jersey Common Pension Fund D increased its position in Ultragenyx Pharmaceutical by 387.2% in the 3rd quarter. State of New Jersey Common Pension Fund D now owns 45,800 shares of the biopharmaceutical company’s stock valued at $1,959,000 after buying an additional 36,400 shares in the last quarter. California Public Employees Retirement System increased its position in Ultragenyx Pharmaceutical by 78.7% in the 3rd quarter. California Public Employees Retirement System now owns 113,815 shares of the biopharmaceutical company’s stock valued at $4,869,000 after buying an additional 50,124 shares in the last quarter. Russell Investments Group Ltd. increased its position in Ultragenyx Pharmaceutical by 0.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 40,005 shares of the biopharmaceutical company’s stock valued at $1,712,000 after buying an additional 332 shares in the last quarter. Finally, First Mercantile Trust Co. increased its position in Ultragenyx Pharmaceutical by 64.4% in the 3rd quarter. First Mercantile Trust Co. now owns 1,892 shares of the biopharmaceutical company’s stock valued at $81,000 after buying an additional 741 shares in the last quarter.

A number of analysts recently commented on RARE shares. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $70.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, December 18th. JPMorgan Chase & Co. reaffirmed a “buy” rating and issued a $75.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, November 6th. BidaskClub raised Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Tuesday. ValuEngine lowered Ultragenyx Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Tuesday, October 29th. Finally, Wedbush boosted their target price on Ultragenyx Pharmaceutical from $71.00 to $75.00 and gave the company an “outperform” rating in a research report on Friday. Four investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The company has an average rating of “Buy” and an average target price of $74.83.

RARE stock opened at $61.13 on Friday. The company has a market capitalization of $3.53 billion, a P/E ratio of -8.46 and a beta of 2.35. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.64 and a current ratio of 6.79. Ultragenyx Pharmaceutical Inc has a 52-week low of $35.41 and a 52-week high of $74.50. The business has a 50-day simple moving average of $53.89 and a two-hundred day simple moving average of $47.87.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.61) by ($0.01). The company had revenue of $35.59 million for the quarter, compared to analyst estimates of $32.31 million. Ultragenyx Pharmaceutical had a negative net margin of 470.18% and a negative return on equity of 52.16%. As a group, sell-side analysts forecast that Ultragenyx Pharmaceutical Inc will post -7.17 earnings per share for the current fiscal year.

In other Ultragenyx Pharmaceutical news, SVP Theodore Alan Huizenga sold 1,000 shares of Ultragenyx Pharmaceutical stock in a transaction dated Tuesday, January 14th. The stock was sold at an average price of $61.00, for a total transaction of $61,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 7.80% of the stock is currently owned by insiders.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D.

Read More: What is a stock portfolio tracker?

Want to see what other hedge funds are holding RARE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ultragenyx Pharmaceutical Inc (NASDAQ:RARE).

Institutional Ownership by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Microsoft Co.  Shares Sold by North Star Asset Management Inc.
Microsoft Co. Shares Sold by North Star Asset Management Inc.
Point View Wealth Management Inc. Lowers Stock Position in Microsoft Co.
Point View Wealth Management Inc. Lowers Stock Position in Microsoft Co.
Secure Asset Management LLC Acquires New Holdings in Microsoft Co.
Secure Asset Management LLC Acquires New Holdings in Microsoft Co.
Microsoft Co.  Stake Increased by Wedgewood Investors Inc. PA
Microsoft Co. Stake Increased by Wedgewood Investors Inc. PA
Palladium Partners LLC Has $59.59 Million Stock Holdings in Microsoft Co.
Palladium Partners LLC Has $59.59 Million Stock Holdings in Microsoft Co.
State of Tennessee Treasury Department Sells 82,917 Shares of Microsoft Co.
State of Tennessee Treasury Department Sells 82,917 Shares of Microsoft Co.


 
© 2006-2020 Zolmax.